Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib
| Autor: | Lori M. Dickerson, Ralph J. Rothenberg, Steven M. Ornstein, Paul J. Nietert |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.drug_class Blood Pressure Cohort Studies Lactones Ambulatory care medicine Ambulatory Care Humans Pharmacology (medical) Sulfones Antihypertensive drug Rofecoxib Antihypertensive Agents Aged Proportional Hazards Models Retrospective Studies Aged 80 and over Sulfonamides Chi-Square Distribution business.industry Retrospective cohort study Odds ratio Middle Aged Blood pressure Celecoxib Anesthesia Ambulatory Hypertension Multivariate Analysis Linear Models Pyrazoles Female business medicine.drug |
| Zdroj: | Pharmacotherapy. 23(11) |
| ISSN: | 0277-0008 |
| Popis: | Study Objective. To determine if changes in blood pressure and changes in class or dosing of antihypertensive drugs were significantly different in patients treated with celecoxib versus rofecoxib, two cyclooxygenase (COX)-2 inhibitors. Design. Retrospective cohort study. Setting. Thirty-one ambulatory care practices that shared an electronic medical record. Patients. Nine hundred sixty men and women over age 55 years with stable hypertension. Intervention. Patients had to have at least a 30-day supply of celecoxib or rofecoxib (any dose) prescribed between July 1, 1999, and June 30, 2000. Measurements and Main Results. Patients were followed for 6 months, and logistic regression and survival models were used to compare outcomes between groups while adjusting for confounders. Baseline characteristics of 517 patients receiving celecoxib and 443 receiving rofecoxib were similar. No significant differences were observed, regardless of the COX-2 inhibitor prescribed, in the proportion of patients whose systolic blood pressure increased by 20 mm Hg, whose diastolic blood pressure increased by 15 mm Hg, or who were prescribed a new class of antihypertensive drug. Compared with patients taking celecoxib, those taking rofecoxib were significantly more likely (odds ratio 1.68, 95% confidence interval 1.09–2.60) to have had the dosage of their antihypertensive drug increased and also the dosage increased sooner (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text